Separately, HC Wainwright initiated coverage on shares of Microbot Medical in a research note on Monday, July 22nd. They set a buy rating and a $10.00 price objective for the company.
Shares of MBOT stock traded down $0.19 on Thursday, reaching $6.55. 31,473 shares of the company were exchanged, compared to its average volume of 61,077. The firm has a 50-day moving average of $5.46. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 0.03. Microbot Medical has a 1 year low of $1.38 and a 1 year high of $19.40.
A hedge fund recently bought a new stake in Microbot Medical stock. Geode Capital Management LLC acquired a new stake in shares of Microbot Medical Inc (NASDAQ:MBOT) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 22,151 shares of the biotechnology company’s stock, valued at approximately $38,000. Geode Capital Management LLC owned approximately 0.51% of Microbot Medical at the end of the most recent quarter. 14.00% of the stock is currently owned by institutional investors and hedge funds.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Read More: Conference Calls and Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.